Renal Transplant Rejection

📋 Key Information Summary

📋

Three temporal categories: Hyperacute (minutes–hours), Acute (days–months), Chronic (months–years); timely distinction is critical for graft survival.
Hyperacute rejection occurs within minutes from preformed circulating antibodies against donor ABO or HLA antigens; graft loss is nearly universal and re-transplantation is usually required.
Acute cellular rejection (ACR) is diagnosed by protocol or for-cause biopsy graded using the Banff 2019 classification (borderline changes, grades IA/IB/IIA/IIB/III).
First-line treatment of ACR: IV methylprednisolone 500 mg daily for 3 days; steroid-resistant ACR warrants anti-thymocyte globulin (Thymoglobulin®).
Antibody-mediated rejection (AMR) is defined by the Banff triad: donor-specific antibody (DSA) positivity, histological evidence of tissue injury (C4d, microvascular inflammation), and graft dysfunction.
AMR first-line therapy: Plasma exchange + IVIg (2 g/kg); adjunctive rituximab and/or bortezomib for refractory cases.
Protocol biopsies at 3, 6, and 12 months post-transplant detect subclinical rejection and improve long-term outcomes — recommended in Australian centres.
DSA monitoring (Luminex single-antigen bead assay) should be performed pre-transplant, post-transplant at defined intervals, and with any graft dysfunction.
Chronic allograft nephropathy involves interstitial fibrosis/tubular atrophy (IF/TA) and transplant glomerulopathy; management focuses on optimising immunosuppression and addressing modifiable risk factors.
ATSI patients experience higher rates of end-stage kidney disease and longer wait times; culturally safe post-transplant follow-up and medication adherence support are essential.
Drug interactions: Tacrolimus and ciclosporin are CYP3A4 substrates — avoid concurrent azole antifungals, grapefruit juice, and monitor for nephrotoxicity with all calcineurin inhibitors.
TMA and BK virus nephropathy must be excluded before diagnosing persistent rejection, as treatment differs significantly.

Introduction & Australian Epidemiology

Renal allograft rejection remains the leading cause of early and late graft loss following kidney transplantation. Despite advances in immunosuppressive therapy, rejection episodes continue to affect approximately 15–25% of kidney transplant recipients in the first year post-transplant in Australia. Rejection is classified into three broad temporal categories — hyperacute, acute, and chronic — each with distinct immunological mechanisms, clinical presentations, and management strategies. Percutaneous graft biopsy with Banff classification remains the gold standard for diagnosis and guides therapeutic decisions.

In Australia, the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) reports that over 1,200 kidney transplants are performed annually, with living donor transplants accounting for approximately 40% of procedures. Acute rejection rates have declined to approximately 10–15% at 12 months with contemporary triple immunosuppression (tacrolimus, mycophenolate, prednisolone), but antibody-mediated rejection continues to be a major cause of late graft loss. The prevalence of chronic kidney disease is disproportionately high among Aboriginal and Torres Strait Islander peoples, and ensuring equitable access to transplantation and culturally safe post-transplant care remains a national priority.

This guideline provides a structured approach to the recognition, investigation, and management of renal transplant rejection, aligned with current Australian and international consensus frameworks including the Banff 2019 classification, Kidney Disease: Improving Global Outcomes (KDIGO) transplant guidelines, and the Transplantation Society of Australia and New Zealand (TSANZ) standards.

Hyperacute vs Acute vs Chronic Rejection

Understanding the temporal and immunological distinctions between rejection types is fundamental to appropriate management. Each category has different pathophysiological mechanisms, clinical trajectories, and therapeutic approaches.

Feature	Hyperacute	Acute	Chronic
Timing	Minutes to hours	Days to 3–6 months (can occur later)	Months to years
Mechanism	Preformed antibodies (ABO or HLA); complement-mediated endothelial injury	T-cell mediated (ACR) or de novo DSA (AMR)	Chronic immune injury, ischaemia, nephrotoxicity, hypertension
Histology	Thrombotic microangiopathy, cortical necrosis	Tubulitis (ACR); C4d+, microvascular inflammation (AMR)	IF/TA (interstitial fibrosis/tubular atrophy), transplant glomerulopathy, vasculopathy
Clinical	Immediate graft non-function, anuria	Rising creatinine, oliguria, fever, graft tenderness	Gradual decline in GFR, proteinuria, hypertension
Treatment	Graft nephrectomy usually required	Steroids, ATG, plasma exchange, IVIg, rituximab	Optimise IS, treat modifiable factors, RAAS blockade
Graft outcome	Almost universal graft loss	Good if treated promptly; steroid-resistant worse	Progressive; 50% lose graft within 5 years of diagnosis

Hyperacute Rejection

Hyperacute rejection results from preformed circulating antibodies directed against donor ABO blood group antigens or HLA class I molecules. These antibodies bind to donor endothelium upon reperfusion, activating complement and causing immediate thrombotic occlusion of the graft vasculature. In the modern era of routine pre-transplant crossmatching (complement-dependent cytotoxicity and virtual crossmatch by Luminex), hyperacute rejection has become exceedingly rare (<0.1%). It manifests as immediate graft non-function with cyanotic, mottled appearance of the kidney intraoperatively. Treatment is immediate graft nephrectomy. Prevention centres on rigorous ABO compatibility testing and HLA crossmatching prior to transplantation.

🚨

Hyperacute rejection is largely preventable. Ensure all pre-transplant crossmatch and ABO compatibility checks are documented and confirmed prior to proceeding with transplantation. A positive crossmatch is an absolute contraindication to deceased-donor transplant unless a desensitisation protocol is in place.

Acute Rejection

Acute rejection is the most clinically significant rejection type encountered in routine practice. It may be T-cell mediated (acute cellular rejection, ACR) or antibody-mediated (AMR), and both types can coexist (mixed rejection). The incidence of acute rejection in the first year post-transplant in Australia is approximately 10–15% with standard triple immunosuppression, with higher rates in sensitised patients, paediatric recipients, and those with poor adherence. Clinical suspicion is raised by a rise in serum creatinine of ≥20% above baseline, oliguria, or graft tenderness, but subclinical rejection — detected on protocol biopsy — occurs in up to 20–30% of stable patients.

Chronic Rejection

Chronic allograft dysfunction encompasses a spectrum of histological changes including interstitial fibrosis and tubular atrophy (IF/TA), transplant glomerulopathy (TG), and chronic transplant vasculopathy. It is now understood that both immune-mediated (subclinical rejection, de novo DSA) and non-immune-mediated (calcineurin inhibitor toxicity, hypertension, diabetes, BK virus nephropathy) factors contribute. Transplant glomerulopathy, characterised by double contours of the glomerular basement membrane on electron microscopy, is increasingly recognised as a manifestation of chronic AMR and is associated with particularly poor graft survival.

Acute Cellular Rejection: Banff Criteria & Treatment

The Banff classification, most recently updated in 2019, provides a standardised histopathological framework for grading allograft rejection. For acute cellular rejection (ACR), the classification focuses on tubulitis (t- and i-scores) and interstitial inflammation. Adequate biopsy sampling (≥7 glomeruli and ≥1 artery on light microscopy) is essential for accurate grading.

Banff 2019 — Acute Cellular Rejection Grading

Borderline

Suspicious for ACR

Minor interstitial inflammation (i0 or i1) with mild tubulitis (t1, t2, or t3); or interstitial inflammation (i2 or i3) with mild tubulitis (t1).

Setting: Optimise immunosuppression; consider pulse steroids if clinically indicated

Grade IA

Moderate Interstitial

Significant interstitial inflammation (>25% of parenchyma, i2 or i3) with moderate tubulitis (t2) affecting at least 3 tubules.

Setting: IV pulse methylprednisolone 500 mg × 3 days

Grade IB

Severe Interstitial

Significant interstitial inflammation (i2 or i3) with severe tubulitis (t3) affecting at least 3 tubules.

Setting: IV pulse methylprednisolone 500 mg × 3 days

Grade IIA

Mild Intimal Arteritis

Intimal arteritis (v1) with or without interstitial inflammation and tubulitis.

Setting: IV pulse methylprednisolone; consider ATG if high-risk features

Grade IIB

Moderate–Severe Intimal Arteritis

Severe intimal arteritis (v2) with or without transmural arteritis or fibrinoid change.

Setting: IV methylprednisolone + ATG (Thymoglobulin®) recommended

Grade III

Transmural Arteritis / Arterial Fibrinoid Change

Transmural arteritis or arterial fibrinoid change (v3) — risk of graft infarction.

Setting: ATG (Thymoglobulin®) + consider plasmapheresis; high risk of graft loss

Treatment of Acute Cellular Rejection

1

First-Line: IV Pulse Corticosteroids

Methylprednisolone 500 mg IV daily for 3 consecutive days. Response assessed by improvement in creatinine within 5–7 days. Effective in 60–80% of ACR episodes.

2

Steroid-Resistant ACR: Anti-Thymocyte Globulin

Rabbit ATG (Thymoglobulin®) 1–1.5 mg/kg/day IV for 5–7 days. Pre-medicate with paracetamol, promethazine, and corticosteroids. Monitor CD3+ T-cell count — target <50 cells/µL. See Drug Card below.

3

Optimise Maintenance Immunosuppression

Ensure tacrolimus trough 8–12 ng/mL (acute phase). Consider conversion from azathioprine to mycophenolate if not already prescribed. Reinforce adherence counselling.

4

Follow-Up Biopsy

Repeat biopsy at 4–6 weeks post-treatment to confirm histological resolution, especially for Banff ≥IIA or any steroid-resistant episode.

💉

Methylprednisolone

Solu-Medrol® · Corticosteroid (pulse)

Adult dose 500 mg IV daily × 3 days (pulse); then taper to oral prednisolone

Paediatric dose 10 mg/kg/day IV (max 500 mg) × 3 days

Route IV infusion over 30–60 minutes

Renal adjustment None required

Key adverse effects Hyperglycaemia, hypertension, GI ulceration, mood disturbance, infection risk

PBS status ✔ PBS General Benefit

💊

Anti-Thymocyte Globulin (Rabbit)

Thymoglobulin® · Polyclonal antibody

Adult dose (ACR) 1–1.5 mg/kg IV daily × 5–7 days (total 5–7 mg/kg)

Paediatric dose 1.5 mg/kg IV daily × 5–7 days

Route IV infusion over 4–6 hours via central line or large-bore peripheral vein

Renal adjustment None required — dose by ideal body weight

Key adverse effects Cytokine release syndrome (first dose), thrombocytopaenia, leucopaenia, CMV reactivation, serum sickness

PBS status ⚠ PBS Authority Required

⚠️

Cytokine release syndrome prevention: Pre-medicate with paracetamol 1 g PO, promethazine 25 mg IV, and hydrocortisone 100 mg IV 30 minutes before each dose of Thymoglobulin®. Monitor for rigors, hypotension, and bronchospasm during infusion.

Antibody-Mediated Rejection (AMR) & DSA

Antibody-mediated rejection (AMR) accounts for approximately 30–40% of acute rejection episodes and is increasingly recognised as the dominant cause of chronic graft loss. The Banff 2019 criteria require three features for definitive AMR diagnosis: (1) circulating donor-specific antibody (DSA) or C4d positivity, (2) histological evidence of acute tissue injury (microvascular inflammation, acute thrombotic microangiopathy, or acute tubular injury in the absence of other causes), and (3) at least one of C4d positivity in peritubular capillaries or validated molecular evidence of endothelial injury.

Donor-Specific Antibodies (DSA)

DSA are antibodies directed against donor HLA antigens (class I: HLA-A, B, C; class II: HLA-DR, DQ, DP). De novo DSA — antibodies that develop post-transplant — are detected in 15–25% of recipients within 5 years and are associated with a 3–5-fold increased risk of graft loss. DSA characteristics that predict worse outcomes include:

High mean fluorescence intensity (MFI): >5,000 on Luminex single-antigen bead assay
Complement-fixing capacity: C1q-binding DSA
IgG subclass: IgG1 and IgG3 are more pathogenic than IgG2/IgG4
HLA class II (especially DQ) DSA: associated with worse chronic AMR outcomes
Multiple DSA specificities and broad sensitisation (high panel reactive antibody, PRA)

Banff 2019 — AMR Classification

Category	DSA / C4d	Histology	Clinical
Active AMR	DSA+ or C4d+	Microvascular inflammation (g+ptc ≥2), TMA, acute tubular injury	Graft dysfunction (rising creatinine, proteinuria)
Chronic active AMR	DSA+ or C4d+	Transplant glomerulopathy (cg >0), peritubular capillary basement membrane multilayering	Chronic graft dysfunction, proteinuria
C4d staining without evidence of rejection	C4d+	No microvascular inflammation, no other injury	Stable graft function
Suspicious for AMR	DSA+ or C4d+ (only one criterion)	Microvascular inflammation without other cause	May be stable or dysfunctional

DSA Monitoring Protocol (Australian Practice)

Pre-transplant

Virtual crossmatch via Luminex single-antigen bead; identify unacceptable antigens. Record baseline DSA MFI values.

1, 3, 6 months

DSA monitoring at each clinic visit with renal function tests. Higher frequency if pre-existing DSA or sensitised recipient.

Annually

Annual DSA screening for all recipients; more frequently if previously sensitised or after any rejection episode.

With any graft dysfunction

Urgent DSA testing + for-cause biopsy with C4d immunofluorescence and electron microscopy.

Management: Steroids, Thymoglobulin, IVIG, Rituximab

Management of renal transplant rejection is guided by the type (cellular vs antibody-mediated), severity (Banff grade), and response to initial therapy. A stepwise approach with escalation for refractory cases is recommended. The following pharmacological agents form the core of rejection treatment in Australian transplant centres.

AMR Treatment Protocol

1

Plasma Exchange (Plasmapheresis)

5–7 sessions on alternate days. Removes circulating DSA and complement. Use 5% albumin as replacement fluid (FFP for active bleeding or TMA).

2

IVIg (High-Dose)

2 g/kg IV (max 140 g) administered after last plasma exchange session, or as standalone if plasmapheresis unavailable. Repeat at 1 g/kg at 4 weeks if DSA persists.

3

Rituximab (Anti-CD20)

375 mg/m² IV × 1–2 doses. Depletes CD20+ B cells; prevents DSA rebound. Consider for refractory AMR or when new DSA develop during treatment.

4

Bortezomib (Proteasome Inhibitor) — Refractory AMR

1.3 mg/m² SC twice weekly × 4 cycles (6 doses). Targets long-lived plasma cells. Off-label use — requires haematology/oncology collaboration. Not PBS-listed for this indication.

5

Eculizumab (Anti-C5) — Selected Cases

1,200 mg IV weekly × 4, then 1,200 mg fortnightly. Complement C5 inhibitor for C4d+/complement-mediated AMR refractory to standard therapy. Extremely costly; restricted availability in Australia.

🧬

Intravenous Immunoglobulin (IVIg)

Intragam P® / Privigen® · Immunoglobulin

Adult dose (AMR) 2 g/kg IV (max 140 g) over 4–6 hours; consider 1 g/kg at 4 weeks if DSA persists

Paediatric dose 2 g/kg IV over 4–6 hours; rate per product guidelines

Route IV infusion; start at 0.5 mL/kg/hr, titrate to max 4 mL/kg/hr as tolerated

Renal adjustment Use sucrose-free preparations (Intragam P®) in renal impairment to avoid osmotic nephropathy

Key adverse effects Headache, rigors, thrombotic risk (ensure adequate hydration), aseptic meningitis, haemolysis (anti-A/anti-B in non-ABO matched products)

PBS status ⚠ PBS Authority Required

💉

Rituximab

Mabthera® / Ruxience® · Anti-CD20 monoclonal antibody

Adult dose 375 mg/m² IV × 1–2 doses (weekly for 1–2 weeks)

Paediatric dose 375 mg/m² IV × 1–4 doses

Route IV infusion; pre-medicate with paracetamol and antihistamine; start at 50 mg/hr, titrate as tolerated

Renal adjustment None required

Key adverse effects Infusion reactions, late-onset neutropaenia (3–6 months), hypogammaglobulinaemia, hepatitis B reactivation (screen before use), PML (rare)

PBS status ⚠ PBS Authority Required

Maintenance Immunosuppression Optimisation During Rejection

In addition to pulse or depleting therapies, maintenance immunosuppression should be reviewed and optimised during any rejection episode:

Tacrolimus: Target trough 8–12 ng/mL during active rejection; reduce to 5–8 ng/mL once resolved.
Mycophenolate mofetil: Increase to maximum tolerated dose (1 g BD for adults; 600 mg/m² BD for paediatrics) if not already maximised.
Prednisolone: After pulse methylprednisolone, continue oral prednisolone 20–25 mg/day and taper over 4–6 weeks to maintenance dose (5–7.5 mg/day).
Adherence assessment: Non-adherence is implicated in 20–30% of late rejection episodes. Use validated tools (BAASIS scale) and consider electronic pill monitoring.

⚠️

Infection prophylaxis during rejection treatment: All patients receiving ATG or intensive immunosuppression require: CMV prophylaxis (valganciclovir 900 mg daily, adjusted for renal function, for 3–6 months depending on donor/recipient CMV status); PJP prophylaxis (trimethoprim-sulfamethoxazole 480 mg daily or 960 mg 3 times/week for 6–12 months); and close monitoring for BK viraemia.

Quick Reference: Rejection Treatment

ACR Borderline–IA

IV methylprednisolone 500 mg × 3 days

3 days pulse + oral taper

Response in 5–7 days

ACR IB–IIB / Steroid-resistant

Thymoglobulin® 1–1.5 mg/kg/day × 5–7 days

5–7 days

Target CD3 <50 cells/µL

Active AMR

PLEX × 5–7 + IVIg 2 g/kg + rituximab

PLEX alternate days; IVIg post-last PLEX

Monitor DSA MFI weekly

Refractory AMR

Bortezomib 1.3 mg/m² SC or eculizumab

Bortezomib: 6 doses over 3 weeks

Discuss with transplant centre

Special Populations

🤰 Pregnancy

Tacrolimus

Safe in pregnancy (Category C); maintain therapeutic monitoring as clearance increases in 2nd/3rd trimester.

Mycophenolate mofetil

CONTRAINDICATED in pregnancy (Category D — teratogenic). Convert to azathioprine ≥6 weeks before planned conception.

Rituximab / Thymoglobulin

Avoid in pregnancy unless life-threatening rejection; discuss with maternal-fetal medicine team.

Prednisolone

Safe at low doses (<20 mg/day); increased risk of gestational diabetes and pre-eclampsia.

👶 Paediatrics

Thymoglobulin®

Dose: 1.5 mg/kg/day IV × 5–7 days; higher per-kg dosing due to larger volume of distribution.

Mycophenolate mofetil

Dose: 600 mg/m² BD (max 1 g BD); suspension available for young children.

Adherence

Adolescents have highest non-adherence rates — consider transition programmes and behavioural support.

👴 Elderly (≥65 years)

ATG / Intensive IS

Increased infection risk; use lower ATG doses (1 mg/kg/day) and consider dose reduction of maintenance IS. Monitor for malignancy (PTLD, skin cancers).

Corticosteroids

Higher risk of steroid complications: diabetes, osteoporosis, fractures. Ensure bone density monitoring and calcium/vitamin D supplementation.

🩺 Impaired Graft Function

IVIg

Use sucrose-free formulation (Intragam P®) to reduce risk of osmotic nephropathy.

Tacrolimus

Narrow therapeutic index; monitor levels closely with each dosing change. Do not use modified-release formulations during unstable rejection.

🫁 Hepatic Impairment

Tacrolimus

Hepatic metabolism — reduce dose in severe liver dysfunction. Monitor levels closely.

Mycophenolate

Enterohepatic recycling impaired in liver disease — consider dose reduction and monitor for GI toxicity.

🦠 Immunocompromised / High Infection Risk

All rejection therapies

Aggressive rejection treatment in already immunocompromised patients dramatically increases infection risk. Ensure CMV/PJP/BK prophylaxis is in place. Monitor FBC, CMV/BK PCR weekly during ATG therapy.

Rituximab

Monitor immunoglobulin levels — if IgG <4 g/L, consider IVIg supplementation to prevent recurrent infections.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience end-stage kidney disease (ESKD) at rates 6–8 times higher than non-Indigenous Australians, with the highest burden in remote and very remote communities. Despite this, transplant rates remain lower and wait times longer for Indigenous Australians. Addressing barriers to transplantation and ensuring culturally safe, equitable post-transplant care — including rejection surveillance and management — is a national health priority.

Access to transplant

Indigenous Australians are under-represented on transplant wait lists. Facilitate early referral to transplant centres (e.g., Royal Adelaide Hospital, Westmead Hospital, Princess Alexandra Hospital). Address systemic barriers including geographic isolation, travel burden, and socioeconomic disadvantage.

Medication adherence

Complex immunosuppressive regimens are challenging in communities with limited pharmacy access and health literacy barriers. Use blister-packed medications, local Aboriginal Health Workers (AHWs) for adherence support, and Telehealth medication reviews.

Follow-up & biopsy access

Protocol and for-cause biopsies require specialist centres. Establish shared-care arrangements with regional centres and use Telehealth for results discussion. Consider DSA monitoring via pathology networks accessible in remote areas.

Infection risk

Higher community prevalence of communicable diseases (hepatitis B, strongyloides, HTLV-1 in Central Australia). Screen pre-transplant and provide appropriate prophylaxis during intensified immunosuppression. Strongyloides hyperinfection risk with ATG — ensure pre-treatment screening and ivermectin if positive.

Cultural safety

Engage Aboriginal Liaison Officers (ALOs) in transplant education, consent processes, and post-transplant care. Respect cultural obligations regarding family decision-making, sorry business, and connection to country when planning follow-up and biopsy schedules.

HLA matching & sensitisation

High rates of sensitisation from prior pregnancies and blood transfusions in Indigenous women may limit donor options. Promote living donation within family networks where culturally appropriate and supported by dedicated transplant coordinators.

📚 References

1. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report: an update on classification of kidney disease pathology and potential biomarkers. Transplantation. 2020;104(10):2048–2068.
2. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1):S1–S103.
3. Transplantation Society of Australia and New Zealand (TSANZ). Clinical Guidelines for Organ Transplantation from Deceased Donors. Version 1.5. 2021.
4. Clayton PA, McDonald SP, Russ GR, Chadban SJ. Long-term outcomes after acute rejection in kidney transplant recipients: an ANZDATA analysis. J Am Soc Nephrol. 2019;30(9):1697–1707.
5. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157–1167.
6. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients — a systematic review. Transplantation. 2012;94(8):775–783.
7. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease: Australian facts. Cat. no. PHE 217. Canberra: AIHW; 2023.
8. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). 46th Annual Report 2023 (Data to 2022). Adelaide, South Australia.
9. Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care. 4th Edition. Melbourne: Kidney Health Australia; 2020.
10. National Aboriginal Community Controlled Health Organisation (NACCHO). Cultural safety in health care — framework. Canberra: NACCHO; 2022.
11. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–283.
12. Schinstock CA, Mannon RB, Budde K, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group. Transplantation. 2020;104(5):911–922.
13. Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol. 2010;21(5):852–858.
14. Grace S, Clayton P, McDonald SP. Increases in renal replacement therapy in Australia and New Zealand: understanding trends in Indigenous and non-Indigenous incidence. Nephrology. 2012;17(1):37–45.